AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26513202 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine extended release (fixed dose 75 mg/day)
Number of subjects: 538
Study 26513202 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine extended release (flexible dose 75-225 mg/day)
Number of subjects: 538
Study 26513202 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 538
Study 26513202 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine extended release (fixed dose)
Number of subjects: 538
Study 26513202 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine extended release (flexible dose)
Number of subjects: 538
Study 23965396 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS-927711 75 mg
Number of subjects: 885
Study 23965396 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS-927711 150 mg
Number of subjects: 885
Study 23965396 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS-927711 300 mg
Number of subjects: 885
Study 23965396 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan 100 mg
Number of subjects: 885
Study 23965396 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 885
Study 23965396 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS-927711 (25-600 mg)
Number of subjects: 885
Study 22467840 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger individuals (20-59 years old)
Number of subjects: 1541
Study 22467840 — intervention group
Group type: COMPARATOR
Intervention: Older individuals (60 years and older)
Number of subjects: 1541
Study 20400912 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole 1.2 mg/kg/day for 4 weeks
Number of subjects: 128
Study 20400912 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study 17910747 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg plus hydrochlorothiazide 12.5 mg (T/HCTZ)
Number of subjects: 840
Study 16260435 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisystemic therapy (MST) for 6 months
Number of subjects: 31
Study 16260435 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 31
Study 16260435 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisystemic therapy (MST)
Number of subjects: 31
Study 11932115 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored communications
Number of subjects: 213
Study 11932115 — intervention group
Group type: COMPARATOR
Intervention: Generic communications
Number of subjects: 213
Study 11932115 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored communications with physician discussion
Number of subjects: 213
Study 11932115 — intervention group
Group type: COMPARATOR
Intervention: Generic communications with physician discussion
Number of subjects: 213
Study 10525755 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine 18.75 mg
Number of subjects: 12
Study 10525755 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine 5 mg
Number of subjects: 12
Study 10525755 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 8544292 — intervention group
Group type: EXPERIMENTAL
Intervention: Lancet point type
Number of subjects: 30
Study 8544292 — intervention group
Group type: COMPARATOR
Intervention: Pencil point type
Number of subjects: 30
Study 1771173 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspartame (500 mg)
Number of subjects: 8
Study 1771173 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose (100 g)
Number of subjects: 8
Study 1771173 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspartame plus sucrose
Number of subjects: 8
Study 1771173 — intervention group
Group type: COMPARATOR
Intervention: Unsweetened beverage
Number of subjects: 8
Study 7067996 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone interview
Number of subjects: 0
Study 7067996 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered, mailed questionnaires
Number of subjects: 0
Study 7067996 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face interview
Number of subjects: 0
Study 31693974 — intervention group
Group type: EXPERIMENTAL
Intervention: MDD patients
Number of subjects: 304
Study 31693974 — intervention group
Group type: EXPERIMENTAL
Intervention: BD patients
Number of subjects: 304
Study 31693974 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of IL-6, IL-8, ST2, sTNFR2, IL-12, and TNF-α
Number of subjects: 304
Study 31693974 — intervention group
Group type: EXPERIMENTAL
Intervention: MDD patients with melancholic features
Number of subjects: 304
Study 31693974 — intervention group
Group type: EXPERIMENTAL
Intervention: sTNFR1 / sTNFR2 ratio
Number of subjects: 304
Study 31375128 — intervention group
Group type: EXPERIMENTAL
Intervention: New Zealand blackcurrant juice (BJ)
Number of subjects: 40
Study 31375128 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo (PLA)
Number of subjects: 40
Study 28736045 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose influenza vaccine
Number of subjects: 92269
Study 28736045 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose influenza vaccine
Number of subjects: 92269
Study 24937346 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider hands as a reservoir of Enterococcus
Number of subjects: 389
Study 24937346 — intervention group
Group type: EXPERIMENTAL
Intervention: Possible intraoperative bacterial transmission events
Number of subjects: 389
Study 24937346 — intervention group
Group type: EXPERIMENTAL
Intervention: Confirmed transmission events
Number of subjects: 389
Study 24937346 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenotypes E5 and E7
Number of subjects: 389
Study 24629994 — intervention group
Group type: EXPERIMENTAL
Intervention: Monovalent human-bovine rotavirus vaccine (116E)
Number of subjects: 6799
Study 24629994 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6799
Study 23059783 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib
Number of subjects: 441
Study 23059783 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 441
Study 23059783 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib and Placebo
Number of subjects: 441
Study 19702643 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Therapy 3 (TT3) with added bortezomib
Number of subjects: 441
Study 19702643 — intervention group
Group type: COMPARATOR
Intervention: Total Therapy 2 (TT2)
Number of subjects: 441
Study 18090468 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceramic-on-metal bearings
Number of subjects: 31
Study 18090468 — intervention group
Group type: COMPARATOR
Intervention: Metal-on-metal bearings
Number of subjects: 31
Study 18090468 — intervention group
Group type: COMPARATOR
Intervention: Ceramic-on-ceramic bearings
Number of subjects: 31
Study 18090468 — intervention group
Group type: COMPARATOR
Intervention: Ceramic-on-polyethylene bearings
Number of subjects: 31
Study 18090468 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory studies
Number of subjects: 31
Study 18090468 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse conditions with rim loading
Number of subjects: 31
Study 15151172 — intervention group
Group type: EXPERIMENTAL
Intervention: TMZ MR 35 mg b.i.d.
Number of subjects: 0
Study 15151172 — intervention group
Group type: COMPARATOR
Intervention: TMZ IR 20 mg t.i.d.
Number of subjects: 0
Study 15151172 — intervention group
Group type: EXPERIMENTAL
Intervention: TMZ MR in dogs and pigs (multiple dose simulations)
Number of subjects: 0
Study 11579646 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin gel (2%)
Number of subjects: 66
Study 11579646 — intervention group
Group type: COMPARATOR
Intervention: Clioquinol cream and/or Lassar paste
Number of subjects: 66
Study 9675961 — intervention group
Group type: EXPERIMENTAL
Intervention: Pr IR 150 mg x 3
Number of subjects: 83
Study 9675961 — intervention group
Group type: EXPERIMENTAL
Intervention: Pr SR 325 mg x 2
Number of subjects: 83
Study 9675961 — intervention group
Group type: EXPERIMENTAL
Intervention: Pr SR 225 mg x 2
Number of subjects: 83
Study 9675961 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 8017357 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (200 micrograms, twice daily for 2 months)
Number of subjects: 48
Study 8017357 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 48
Study 8017357 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 2872793 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous hydralazine (5 to 30 mg)
Number of subjects: 18
Study 2872793 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nifedipine (20 to 80 mg)
Number of subjects: 18
Study 31889507 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) testing
Number of subjects: 169
Study 31889507 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical scores (Centor and FeverPAIN)
Number of subjects: 169
Study 31889507 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 169
Study 29572695 — intervention group
Group type: EXPERIMENTAL
Intervention: Swim-up method
Number of subjects: 65
Study 27546364 — intervention group
Group type: EXPERIMENTAL
Intervention: Early laparoscopic cholecystectomy within 72 hours after symptoms
Number of subjects: 62
Study 27546364 — intervention group
Group type: COMPARATOR
Intervention: Delayed cholecystectomy after 6-8 weeks (control group)
Number of subjects: 62
Study 24848492 — intervention group
Group type: COMPARATOR
Intervention: FR+inactive (low physical activity, approximately 4500 steps per day)
Number of subjects: 22
Study 24848492 — intervention group
Group type: EXPERIMENTAL
Intervention: FR+active (high physical activity, approximately 12,500 steps per day)
Number of subjects: 22
Study 22588154 — intervention group
Group type: EXPERIMENTAL
Intervention: CT screening with five annual low-dose CT scans
Number of subjects: 4104
Study 22588154 — intervention group
Group type: COMPARATOR
Intervention: No screening (control)
Number of subjects: 4104
Study 20718170 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg orally
Number of subjects: 120
Study 20718170 — intervention group
Group type: EXPERIMENTAL
Intervention: Parecoxib 40 mg intravenously
Number of subjects: 120
Study 20718170 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 18572758 — intervention group
Group type: EXPERIMENTAL
Intervention: 27-gauge needle
Number of subjects: 60
Study 18572758 — intervention group
Group type: EXPERIMENTAL
Intervention: 31-gauge needle
Number of subjects: 60
Study 18572758 — intervention group
Group type: EXPERIMENTAL
Intervention: Gas-powered, needle-free injection device (NFID)
Number of subjects: 60
Study 18569233 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxitropium (200 microg by MDI)
Number of subjects: 44
Study 18569233 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium (18 microg by Handihaler)
Number of subjects: 44
Study 18569233 — intervention group
Group type: COMPARATOR
Intervention: Ipratropium (40 microg by MDI)
Number of subjects: 44
Study 18569233 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of PD(15)FEV(1)
Number of subjects: 44
Study 18569233 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-response slope
Number of subjects: 44
Study 18569233 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between PD(15)FEV(1) and FEV(1)% increase
Number of subjects: 44
Study 15519014 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (initiated before ACEI)
Number of subjects: 78
Study 15519014 — intervention group
Group type: COMPARATOR
Intervention: ACEI (initiated after carvedilol)
Number of subjects: 78
Study 10783403 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomized 4% lidocaine
Number of subjects: 40
Study 10783403 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline solution)
Number of subjects: 40
Study 9084344 — intervention group
Group type: EXPERIMENTAL
Intervention: Piracetam 4.8 g/day with intensive language therapy for 6 weeks
Number of subjects: 66
Study 9084344 — intervention group
Group type: COMPARATOR
Intervention: Placebo with intensive language therapy for 6 weeks
Number of subjects: 66
Study 8251285 — intervention group
Group type: EXPERIMENTAL
Intervention: Edrophonium 0.1, 0.2, 0.4, or 1 mg kg‐1
Number of subjects: 64
Study 8251285 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine 0.005, 0.01, 0.02, or 0.05 mg kg‐1
Number of subjects: 64
Study 8251285 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous recovery (Control)
Number of subjects: 64
Study 3711547 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise-induced asthma with endogenous adrenergic activity
Number of subjects: 10
Study 3711547 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosol of norepinephrine during exercise-induced asthma
Number of subjects: 10
Study 3711547 — intervention group
Group type: COMPARATOR
Intervention: Isocapnic hyperventilation (control)
Number of subjects: 10
Study 31256599 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated Linoleic Acid (CLA) supplementation (3000 mg daily in 3 doses)
Number of subjects: 54
Study 30029523 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose 'Benifuuki' extract (676 mg of catechins)
Number of subjects: 159
Study 30029523 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose 'Benifuuki' extract (322 mg of catechins)
Number of subjects: 159
Study 30029523 — intervention group
Group type: COMPARATOR
Intervention: No 'Benifuuki' extract (control group)
Number of subjects: 159
Study 27472361 — intervention group
Group type: EXPERIMENTAL
Intervention: Casein protein (CAS, 120 kcal)
Number of subjects: 12
Study 27472361 — intervention group
Group type: COMPARATOR
Intervention: Non-nutritive placebo (PLA)
Number of subjects: 12
Study 27472361 — intervention group
Group type: EXPERIMENTAL
Intervention: Casein protein (CAS)
Number of subjects: 12
Study 24213961 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation (tDCS)
Number of subjects: 40
Study 24213961 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS (Control)
Number of subjects: 40
Study 22404221 — intervention group
Group type: EXPERIMENTAL
Intervention: Swallowing exercise (placing a milk bolus of 0.05‐0.2 mL on the tongue)
Number of subjects: 0
Study 22404221 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucking exercise (active sucking on a pacifier)
Number of subjects: 0
Study 22404221 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 0
Study 19445637 — intervention group
Group type: EXPERIMENTAL
Intervention: Portable media consoles
Number of subjects: 0
Study 19445637 — intervention group
Group type: COMPARATOR
Intervention: Television-based consoles
Number of subjects: 0
Study 17218570 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal noninvasive mechanical ventilation (NIMV) for 3 months
Number of subjects: 23
Study 17218570 — intervention group
Group type: COMPARATOR
Intervention: Sham NIMV for 3 months
Number of subjects: 23
Study 15482044 — intervention group
Group type: EXPERIMENTAL
Intervention: ABCT with interventions encouraging Alcoholics Anonymous (AA) involvement (AA/ABCT)
Number of subjects: 90
Study 15482044 — intervention group
Group type: EXPERIMENTAL
Intervention: ABCT with relapse prevention techniques (RP/ABCT)
Number of subjects: 90
Study 15482044 — intervention group
Group type: COMPARATOR
Intervention: Alcohol behavioral couples therapy (ABCT)
Number of subjects: 90
Study 15482044 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments (ABCT, RP/ABCT, AA/ABCT)
Number of subjects: 90
Study 21236721 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose/short-term hepatitis B vaccination schedules
Number of subjects: 0
Study 21236721 — intervention group
Group type: EXPERIMENTAL
Intervention: New immunogenic formulations of hepatitis B vaccine
Number of subjects: 0
Study 21236721 — intervention group
Group type: EXPERIMENTAL
Intervention: Early vaccination of potential transplant candidates
Number of subjects: 0
Study 9596305 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 50 microg twice a day for 3 days
Number of subjects: 16
Study 9596305 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 100 microg twice a day for 3 days
Number of subjects: 16
Study 9596305 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol (both dosages)
Number of subjects: 16
Study 7829764 — intervention group
Group type: EXPERIMENTAL
Intervention: TRH tests administered before, during, and after ECT
Number of subjects: 31
Study 7829764 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial TSH response to TRH
Number of subjects: 31
Study 3122559 — intervention group
Group type: EXPERIMENTAL
Intervention: Early initiation of enteral nutrition
Number of subjects: 43
Study 3122559 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 43
Study 28833808 — intervention group
Group type: EXPERIMENTAL
Intervention: Trenonacog alfa (IB1001)
Number of subjects: 76
Study 27278935 — intervention group
Group type: EXPERIMENTAL
Intervention: Cash and in-kind food transfer programme
Number of subjects: 0
Study 26051569 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure backrest for 1 month
Number of subjects: 64
Study 26051569 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 64
Study 26051569 — intervention group
Group type: EXPERIMENTAL
Intervention: Preferred acupressure backrest for 1 month
Number of subjects: 64
Study 23018904 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin DPI 32.5 mg
Number of subjects: 124
Study 23018904 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study 20459634 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity and dietary pattern interventions
Number of subjects: 1500
Study 20459634 — intervention group
Group type: COMPARATOR
Intervention: Sedentary lifestyle
Number of subjects: 1500
Study 18403102 — intervention group
Group type: EXPERIMENTAL
Intervention: Irrigation with ISO 0.1 microg/mL
Number of subjects: 12
Study 18403102 — intervention group
Group type: COMPARATOR
Intervention: Irrigation with saline
Number of subjects: 12
Study 16788315 — intervention group
Group type: EXPERIMENTAL
Intervention: rFVIIa (40 microg/kg)
Number of subjects: 76
Study 16788315 — intervention group
Group type: COMPARATOR
Intervention: Standard haemostatic replacement therapy (placebo)
Number of subjects: 76
Study 16788315 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 76
Study 12135219 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg oestradiol implants
Number of subjects: 21
Study 12135219 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 21
Study 9925060 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg/d of beclomethasone dipropionate (BDP)
Number of subjects: 30
Study 9925060 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 7572574 — intervention group
Group type: COMPARATOR
Intervention: rTPA alone (100 mg in 3 hours)
Number of subjects: 60
Study 7572574 — intervention group
Group type: EXPERIMENTAL
Intervention: rTPA plus nitroglycerin (100 micrograms/min)
Number of subjects: 60
Study 2180474 — intervention group
Group type: EXPERIMENTAL
Intervention: Early treatment with oxprenolol or oxprenolol plus dihydralazine
Number of subjects: 155
Study 2180474 — intervention group
Group type: COMPARATOR
Intervention: Control group with matching placebos
Number of subjects: 155
Study 2180474 — intervention group
Group type: EXPERIMENTAL
Intervention: Early treatment with oxprenolol
Number of subjects: 155
Study 2180474 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 155
Study 7000303 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacampicillin 1.6g with probenecid 1g
Number of subjects: 0
Study 7000303 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin 3.5g with probenecid 1g
Number of subjects: 0
Study 30225529 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram 10 mg/day for 8 weeks
Number of subjects: 41
Study 30225529 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 41
Study 28358815 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine 50mg for 24, 36 or 48 weeks with steroid treatment (oral prednisolone for 20 weeks)
Number of subjects: 279
Study 28358815 — intervention group
Group type: COMPARATOR
Intervention: Steroid treatment (oral prednisolone for 20 weeks)
Number of subjects: 279
Study 28358815 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine treatment for 48 weeks
Number of subjects: 279
Study 28358815 — intervention group
Group type: COMPARATOR
Intervention: Steroid treatment
Number of subjects: 279
Study 28358815 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine and Dapsone together
Number of subjects: 279
Study 28358815 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment with steroids and azathioprine
Number of subjects: 279
Study 25981347 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocoa flavanols (CF) at doses of 5.3 mg and 10.7 mg total CF/kg body weight (BW)
Number of subjects: 40
Study 25981347 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen (1 g) as control
Number of subjects: 40
Study 25981347 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocoa flavanols (CF)
Number of subjects: 40
Study 23321963 — intervention group
Group type: EXPERIMENTAL
Intervention: email
Number of subjects: 20180
Study 23321963 — intervention group
Group type: EXPERIMENTAL
Intervention: letter
Number of subjects: 20180
Study 23321963 — intervention group
Group type: COMPARATOR
Intervention: reports
Number of subjects: 20180
Study 23321963 — intervention group
Group type: EXPERIMENTAL
Intervention: email (patients <18 years)
Number of subjects: 20180
Study 23321963 — intervention group
Group type: EXPERIMENTAL
Intervention: letter (patients ≥18 years)
Number of subjects: 20180
Study 23321963 — intervention group
Group type: COMPARATOR
Intervention: patient-reported assessments
Number of subjects: 20180
Study 21415263 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised treadmill training for 12 weeks at home, exercising twice a week at an intensity of 66% of HR(peak)
Number of subjects: 34
Study 21415263 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 34
Study 19548433 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine (TCM)
Number of subjects: 336
Study 19548433 — intervention group
Group type: COMPARATOR
Intervention: Estazolam (Control)
Number of subjects: 336
Study 19548433 — intervention group
Group type: EXPERIMENTAL
Intervention: Both TCM and Estazolam
Number of subjects: 336